Supplemental Material, Gimeno_#2_Appendix_A_FINAL - Protocol for <i>N</i>-of-1 trials with replications across therapists for childhood-onset dystonia rehabilitation: Study 2

<p>Supplemental Material, Gimeno_#2_Appendix_A_FINAL for Protocol for <i>N</i>-of-1 trials with replications across therapists for childhood-onset dystonia rehabilitation: Study 2 by Hortensia Gimeno, Helene J. Polatajko, Victoria Cornelius, Jean-Pierre Lin, and Richard G. Brown in Canadian Journal of Occupational Therapy</p

Supplemental Material, Gimeno_#1_Appendix_A_Supplementary_FINAL - Protocol for <i>N</i>-of-1 trials proof of concept for rehabilitation of childhood-onset dystonia: Study 1

<p>Supplemental Material, Gimeno_#1_Appendix_A_Supplementary_FINAL for Protocol for <i>N</i>-of-1 trials proof of concept for rehabilitation of childhood-onset dystonia: Study 1 by Hortensia Gimeno, Helene J. Polatajko, Victoria Cornelius, Jean-Pierre Lin, and Richard G. Brown in Canadian Journal of Occupational Therapy</p

Supplemental Material, Gimeno_#1_Appendix_C_Supplementary_FINAL_FINAL - Protocol for <i>N</i>-of-1 trials proof of concept for rehabilitation of childhood-onset dystonia: Study 1

<p>Supplemental Material, Gimeno_#1_Appendix_C_Supplementary_FINAL_FINAL for Protocol for <i>N</i>-of-1 trials proof of concept for rehabilitation of childhood-onset dystonia: Study 1 by Hortensia Gimeno, Helene J. Polatajko, Victoria Cornelius, Jean-Pierre Lin, and Richard G. Brown in Canadian Journal of Occupational Therapy</p

Supplemental Material, Gimeno_#1_Appendix_B_FINAL_FINAL - Protocol for <i>N</i>-of-1 trials proof of concept for rehabilitation of childhood-onset dystonia: Study 1

<p>Supplemental Material, Gimeno_#1_Appendix_B_FINAL_FINAL for Protocol for <i>N</i>-of-1 trials proof of concept for rehabilitation of childhood-onset dystonia: Study 1 by Hortensia Gimeno, Helene J. Polatajko, Victoria Cornelius, Jean-Pierre Lin, and Richard G. Brown in Canadian Journal of Occupational Therapy</p

White matter maps showing regions of significant decreased fractional anisotropy and increased mean diffusivity in MSA patients when compared to healthy controls and PD (Bonferroni corrected alpha = 0.0167).

<p>Background image corresponds to the mean fractional anisotropy image of all subjects in standard MNI152 space (radiological view). Fractional anisotropy white matter skeleton is represented by green voxels. Blue voxels represent regions of decreased FA and yellow voxels represent regions of increased MD in the PSP group.</p

White matter regions of fractional anisotropy changes between PSP, MSA, PD and HC.

<p>All results reported at p<0.05, TFCE and Bonferroni corrected (corrected alpha = 0.0167).</p><p>White matter regions of fractional anisotropy changes between PSP, MSA, PD and HC.</p

White matter maps showing regions of significant correlation between mean diffusivity and measures of disease severity (Bonferroni corrected alpha = 0.0167).

<p>Top row coronal view, bottom row axial view. Background image corresponds to the mean fractional anisotropy image of all subjects in standard MNI152 space (radiological view). Fractional anisotropy white matter skeleton is represented by green voxels. Blue voxels represent regions of decreased FA and yellow voxels represent regions of increased MD in the PSP group.</p

Demographic and clinical data of control subjects and patients with PD, MSA and PSP.

<p>* For patients taking levodopa drug treatment, scores given in the ‘on’ state.</p>†<p>From Parkinson's Plus Scale (Cerebellar Score, maximum 24; Occulomotor Score, maximum 21).</p><p>MSA  =  multiple systems atrophy; PSP  =  progressive supranuclear palsy; PD  =  Parkinson's disease; MSA-P  =  multiple system atrophy parkinsonian variant; MSA-C  =  multiple system atrophy cerebellar variant; H&Y  =  Hoehn and Yahr; ADL  =  activities of daily living; UPDRS III  =  Unified Parkinson Disease Rating Scale-part III.</p><p>Demographic and clinical data of control subjects and patients with PD, MSA and PSP.</p

White matter regions of mean diffusivity changes between PSP, MSA, PD and HC.

<p>All results reported at p<0.05, TFCE and Bonferroni corrected (corrected alpha 0.0167).</p><p>White matter regions of mean diffusivity changes between PSP, MSA, PD and HC.</p

White matter maps showing regions of significant decreased fractional anisotropy and increased mean diffusivity in PSP patients when compared to healthy controls, PD and MSA (Bonferroni corrected alpha = 0.0167).

<p>Background image corresponds to the mean fractional anisotropy image of all subjects in standard MNI152 space (radiological view). Fractional anisotropy white matter skeleton is represented by green voxels. Blue voxels represent regions of decreased FA and yellow voxels represent regions of increased MD in the PSP group.</p